by Daniel X. Thomas
The patent relates generally to agents and devices for promoting haemostasis and tissue sealing materials and, more particularly, to synthetic peptides having strong haemostatic properties and tissue sealing properties in combination with scaffolds, such as gelatine based haemostatic scaffolds.
Brief outline of the case
The patent was maintained according to AR 4 by the OD.
by Daniel X. Thomas
The patent relates to a fabric treatment composition, exactly to a softener.
Brief outline of the case
Opponent 2 appealed the decision to reject the opposition.
In appeal there was a long discussion about experimental data submitted by all the parties. Those data were all post-published.
There was unanimity among the parties that D1=DE 10 2006 034 051,
by Daniel X. Thomas
The patent relates to a “Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis”.
Brief outline of the case
The OD decided maintenance according to AR 16 as the claims as granted and AR 1-15 where lacking sufficiency.
The opponent appealed the decision of the OD.
by Daniel X. Thomas
The patent relates to a “flexible” electrical connector for connection to an electrical element on a substrate such as glazing in a vehicle.
Brief outline of the case
Opponent 1 appealed the decision of maintenance according to AR3.
The board decided to revoke the patent as the subject-matter of claim 1 as maintained and of AR1 was lacking IS over E1=DE 103 01 352 + D3=US 5,920,125.
by Daniel X. Thomas
The UCL Institute of Brand and Innovation Law chaired by Sir Robin Jacob organised a forum discussion on the topic: EPO and UPC: Friends or Foes?
The panel consisted of:
Dr Ingo Beckedorf (Chairman of Legal Board of Appeal, EPO)
Florence Butin (President of CFI of UPC)
Edward Oates (partner at Carpmaels and Ransford LLP)
Annsley Merelle Ward (partner at Wilmer Hale)
Chair: Professor Sir Robin Jacob (UCL Faculty of Laws and Director of the UCL Institute of Brand and Innovation Law)
I booked a ticket to follow the discussion on line.